Welcome to my Digital Health Regulatory Pathways Master Class series. This series breaks down the core concepts every founder should understand about US and EU regulatory pathways, from what qualifies as a medical device to how risk classification affects your timeline, cost, and market strategy.

You’ve landed on #1 of this series, where I explain why understanding regulatory pathways and having a strategy at the outset is so incredibly important for Digital Helath founders.  

Why Regulatory Strategy Can Make or Break Your Digital Health Startup

 

This is the very first post in my Demystifying Regulatory Pathways for Digital Health series.

If you’re building a digital health product—especially something involving Software as a Medical Device (SaMD) or an AI-powered healthcare tool—your regulatory strategy isn’t just a compliance checkbox. It’s a make-or-break part of your company’s speed to market, product roadmap, and investor appeal.

This post kicks off a blog series titled Digital Health Regulatory Pathways Master Class, written specifically for founders navigating FDA and MDR pathways for the first time. It’s meant to give you a working foundation in regulatory strategy—something you can build on as your product matures.

Is This Series for You?

 

This series is for you if:

  • You’re a digital health founder with a SaMD or AI/ML product
  • You plan to launch in the U.S., the EU, or both
  • You don’t have a regulatory lead on your team
  • You’re unclear about how the FDA and MDR processes work

 

If any of the above describe your situation, this series will help you get grounded—without jargon, and without assuming you already know the basics.

Why You Should Think About Regulatory Strategy Now

 

A lot of early-stage founders treat FDA or EU MDR approval as something to deal with later—or something a consultant will eventually take care of. But here’s the reality:

Your regulatory strategy affects your product’s scope, your budget, your time to market, and even your valuation. Getting it right early can:

  • Save you money — by avoiding the wrong (and more expensive) pathway
  • Save you time — regulatory timelines range from 3 months to 2+ years depending on classification
  • Strengthen your investor pitch — especially if you’ve met regulatory milestones
  • Prevent painful rework — on documentation, testing, and even product design

 

Especially if you’re working on AI tools, SaMD platforms, or any kind of device that informs treatment trajectories, the consequences of delaying your regulatory plan can be expensive—and hard to reverse.

What You’ll Learn in This Series

 

Each post in this series tackles one foundational concept you’ll need to navigate regulation as a digital health startup:

  • What qualifies as a medical device (and what doesn’t)
  • The key differences between FDA (United States) and MDR (European Union) regulatory processes
  • How to determine your product’s risk class under each system
  • What your risk class means for documentation, cost, and clinical evidence
  • A breakdown of the 510(k), De Novo, PMA (in the case of the FDA), and Notified Body (for the EU) pathways
  • What early action steps you can take to avoid surprises and stay fundable

 

By the end of the series, you should have a better understanding of the different regulatory pathways and a strong inkling of which makes the most sense for your product. At the very least, you will be conversant in ‘’regulatory speech” and feel more confident engaging in this area more generally.

Why I Wrote This

 

Too many digital health startups hit roadblocks at the very moment they should be gaining traction—because they missed or misunderstood regulatory requirements early on. Or, they completely failed to realize that launching in the US versus the EU could have saved them hundreds of thousands of Euro. It’s just smart to understand how the two systems work and understand the paths that make the most sense for your product, and what that pathway involves. Hopefully this series will make that first step a little less painful for you.

This series is here to give you the basic working knowledge to:

  • Understand what kind of product you’re actually building
  • Choose the right market entry point (U.S. or EU)
  • Plan out your documentation and validation strategy
  • Communicate clearly with both investors and regulators

 

If you can speak confidently about your regulatory pathway, you’re already ahead of the curve.

Coming Up Next: What Actually Counts as a Medical Device?

In the next post, we’ll tackle a surprisingly slippery question: is your digital health product even considered a medical device under FDA or MDR definitions?

(Spoiler: your fitness tracker probably isn’t. But your AI-powered triage assistant probably is.)

Ask me anything.

Really.  If you have a question, submit it through this form. I will try my best to respond within a business day. Good questions will get featured on my FAQs list. 

Still have questions after exploring? Set up a quick meeting with me here.